Abstract
The aims of this study were to investigate the expression of transforming growth factor-β1 (TGF-β1) and α-smooth muscle actin (α-SMA) in surgical resection specimens from nonsmall cell lung cancer (NSCLC) and to evaluate the prognostic significance of this gene expression in stromal fibroblasts for patients with clinical stage I–IIIA NSCLC. The immunohistochemical expression of TGF-β1 and α-SMA was evaluated in 78 formalin-fixed paraffin-embedded tumor specimens from clinical stage I–IIIA NSCLC. Correlations between this gene expression and the clinicopathologic characteristics were determined by chi-square test. The prognostic impact of this gene expression in stromal fibroblasts with regard to overall survival (OS) was determined by Kaplan-Meier and Cox hazard proportional model. The percentages of high TGF-β1 expression in stromal fibroblasts and cancer cells were 19.2 % (15/78) and 35.9 % (28/78), respectively. There were 28.2 % (22/78) of patients with high α-SMA expression in stromal fibroblasts. The analysis revealed a significant positive association between TGF-β1 expression in stromal fibroblasts and in cancer cells (χ 2 = 4.86, p = 0.03). No significant association was found between TGF-β1 in cancer cells and α-SMA expression in stromal fibroblasts (χ 2 = 0.978, p = 0.326). The 3-year OS rates with low and high TGF-β1 expression in stromal fibroblasts were 52.4 and 26.7 %, respectively (χ 2 = 5.42, p = 0.019). The 3-year OS rates with low and high α-SMA expression in stromal fibroblasts were 53.9 and 31.0 %, respectively (χ 2 = 5.01, p = 0.025). The multivariate analysis revealed that clinical stage and TGF-β1 and α-SMA expression levels in stromal fibroblasts were identified as independent predictive factors of OS. The results suggest that the expression level of TGF-β1 and α-SMA in stromal fibroblasts may have prognostic significance in patients with clinical stage I–IIIA NSCLC after curative resection.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
Haithcock BE, Stinchcombe TE, Socinski MA. Treatment of surgically resectable non-small-cell lung cancer in elderly patients. Clin Lung Cancer. 2009;10:405–9.
Williams BA, Sugimura H, Endo C, et al. Predicting postrecurrence survival among completely resected non small cell lung cancer patients. Ann Thorac Surg. 2006;81:1021–7.
Kim MP, Chen Y, Bekele BN, et al. Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg. 2011;92:1044–50.
Konopa K. Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer? Ann Oncol. 2010;7:199–202.
Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumor cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012;31:195–208.
Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25:30–8.
Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol. 2002;3:349–63.
Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of coin. Am J Cancer Res. 2011;1:482–97.
Mantoni TS, Lunardi SL, AI-Assar O, et al. Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling. Cancer Res. 2011;71:3453–8.
Xu Z, Wang S, Wu M, et al. TGF-β1 and HGF protein secretion by esophageal squamous epithelial cells and stromal fibroblasts in oesophageal carcinogenesis. Oncol Lett. 2013;6:401–6.
Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-β1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103–11.
Hazelbag S, Gorter A, Kenter GG, et al. Transforming growth factor-β1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol. 2002;33:1193–9.
Hawinkels LJAC, Paauwe M, Verspage HW, et al. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts. Oncogene. 2012. doi:10.1038/onc.2012.536.
Peng Y, Li Z, Li Z. GRP78 secreted by tumor cells stimulates differentiation of bone marrow mesenchymal stem cells to cancer-associated fibroblasts. Biochem Biophys Res Commun. 2013;440:558–63.
Liu C, Wu JF. Expression of TGF-β1, HIF-1α, VEGF and their clinical significance of gastric cancer. J Clin Exp Pathol. 2013;29:733–6.
Fuyuhiro Y, Yashiro M, Noda S, et al. Myofibroblasts are associated with the progression of scirrhous gastric carcinoma. Exp Ther Med. 2010;1:547–51.
Zhi K, Shen X, Zhang H, et al. Cancer-associated fibroblasts are positively correlated with metastasis potential of human gastric cancers. J Exp Clin Cancer Res. 2010;29:66–74.
Yamashita M, Ogawa T, Zhang X, et al. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer. 2012;19:170–6.
Valach J, Fik Z, Strnad H, et al. Smooth muscle actin-expressing stromal fibroblasts in head and neck squamous cell carcinoma: Increased expression of galectin-1 and induction of poor prognosis factors. Int J Cancer. 2012;131:2499–508.
Tsamandas AC, Kardamakis D, Ravazoula P, et al. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol. 2004;180:201–8.
Vagenas K, Spyropoulos C, Gavala V, et al. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res. 2007;139:182–8.
Soufla G, Sifakis S, Porichis F, et al. Prognostic value of tgfb1 protein in endometrioid adenocarcinoma. Eur J Clin Investig. 2013;43:79–90.
Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-beta and stromal cell-derived factor (SDF-1) signaling derives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA. 2010;107:20009–14.
Fuyuhiro Y, Yashiro M, Noda S, et al. Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells. Br J Cancer. 2011;105:996–1001.
Brenmoehl J, Miller SN, Hofmann C, et al. Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol. 2009;15:1431–42.
Rosenthal E, McCrory A, Talbert M, et al. Elevated expression of TGF-β1 in head and neck cancer-associated fibroblasts. Mol Carcinogen. 2004;40:116–21.
Acknowledgments
This study was supported by grants from the Priority Academic Program Development of Jiangsu Higher Education Institutions and Jiangsu Province’s Key Medical Department in 2011.
Conflicts of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, Y., Zou, L., Zhang, Y. et al. Transforming growth factor-β1 and α-smooth muscle actin in stromal fibroblasts are associated with a poor prognosis in patients with clinical stage I–IIIA nonsmall cell lung cancer after curative resection. Tumor Biol. 35, 6707–6713 (2014). https://doi.org/10.1007/s13277-014-1908-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-1908-y